Cantor Fitzgerald reiterates Pharvaris stock rating after trial data

Pharvaris's Phase 3 CHAPTER-3 trial showed deucrictibant reduced hereditary angioedema attack rates by 83% overall and 87% in Type 1/2 patients, supporting a favorable launch outlook. Cantor Fitzgerald reiterated an Overweight rating and $65 target, while other firms set targets from $44 to $79; PHVS traded at $39.12, up nearly 64% over the past year. Management clarified that the reported Grade 4 and serious adverse events referred to the same non-liver-related patient event, mitigating a key safety concern.

Analysis

PHVS’s upside now depends less on incremental efficacy headlines and more on whether deucrictibant can displace established prophylaxis rather than merely serve oral-preferring switch patients. Takeda’s Takhzyro franchise (TAK) has deeply embedded prescriber and payer access; an oral option could pressure its retention over 6-18 months, but payer step-edits and the need for durable real-world safety will likely limit near-term conversion. The more immediate competitive read-through is negative for early-stage oral HAE prevention programs, including Astria (ATXS), where differentiation must now be demonstrated on dosing, safety, or patient selection rather than convenience alone.

The analyst-target cluster is not independently validating commercial value: it assumes regulatory execution, a clean label, and reimbursement sufficient to support a premium rare-disease launch. With PHVS near prior highs, the next 1-3 month catalyst is detailed dataset scrutiny—discontinuations, liver laboratory trends, attack-rate consistency across prior prophylaxis exposure, and open-label durability—not another reiteration. Any FDA feedback implying a larger safety database, or evidence that efficacy attenuates in patients switching from Takhzyro, would compress the launch multiple rapidly.

Contrarian view: the market may be over-crediting the addressable population. Strong attack reduction does not automatically translate into broad switching when controlled patients face administrative friction and physicians prioritize avoidance of breakthrough laryngeal events. Conversely, if PHVS demonstrates rapid onset, low breakthrough-event severity, and clean long-term hepatic monitoring, oral prophylaxis could expand treatment penetration among patients currently reluctant to use injections—an upside pathway not captured by simple share-take assumptions.

Key Decisions for Investors

• Maintain a tactical long PHVS only on pullbacks below $36, with a 3-6 month target of $50-55 and a risk stop below $32. This requires confirmation of detailed safety/discontinuation data and a credible regulatory filing timetable; absent those, do not chase near the 52-week high.
• Use a defined-risk event structure rather than outright momentum exposure: buy PHVS 6-month $40/$55 call spreads after a filing-date or regulator-interaction catalyst is disclosed. The structure limits premium loss if post-data consolidation persists while retaining upside to label and launch-value re-rating.
• Watch TAK for evidence of defensive contracting or revised Takhzyro growth commentary over the next two earnings cycles. A PHVS launch is not yet sufficient for a TAK short; initiate a PHVS-long/TAK-underweight pair only if payer coverage or switch intent becomes visible, since TAK’s diversified earnings base reduces near-term sensitivity.
• Avoid treating the cited safety anecdote as de-risking. Set an alert for any new hepatic signal, serious adverse-event imbalance, or FDA request for additional exposure data; any of these would invalidate the near-term PHVS long thesis and could justify closing exposure before regulatory timing resets.